SCHEMBL30516379

SCHEMBL30516379

FC(F)(F)c1cc2c(Br)cccc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.54
AHR P35869 1/20 0.46
KIF11 P52732 3/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
FLT3 P36888 1/20 0.39
ITK Q08881 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NOS1 P29475 1/20 0.39
AXL P30530 1/20 0.39
HRH4 Q9H3N8 1/20 0.38
ENPP3 O14638 1/20 0.38
ENPP1 P22413 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL993353 1.00 KDM4E (0.54) KDM4EAHRKIF11CRHBPCRHR2
SCHEMBL12755269 0.81 AHR (0.46) KDM4EAHRKIF11FLT3ITK
SCHEMBL2006082 0.78 KDM4E (0.54) KDM4EKIF11CRHBPCRHR2MEN1
SCHEMBL17537352 0.78 KDM4E (0.54) KDM4EKIF11CRHBPCRHR2FLT3
SCHEMBL28357141 0.74 KDM4E (0.50) KDM4ECRHBPCRHR2FLT3MEN1
SCHEMBL30065614 0.73 KDM4E (0.53) KDM4EAHRCRHBPCRHR2MEN1
SCHEMBL3919144 0.71 KDM4E (0.51) KDM4EKIF11CRHBPCRHR2MEN1
SCHEMBL31070422 0.71 AHR (0.45) KDM4EAHRFLT3ITKALDH1A1
SCHEMBL31098173 0.71 GAA (0.50) KDM4EAHRKIF11FLT3ITK
SCHEMBL21356683 0.71 AHR (0.45) KDM4EAHRFLT3ITKALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12319682-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2025-06-03 US disclosed
US-20240287056-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS Adamed Pharma S.A (PL) 2024-08-29 US disclosed
CN-112041300-B Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists 阿达梅德制药公司 2023-07-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12319682-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists HTR2A, HTR6, HTR2C KDM4E 1520/4885AHR 167/4885KIF11 4611/4885
US-20240287056-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS HTR2A, HTR6, HTR2C KDM4E 1506/4885AHR 170/4885KIF11 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.